Post-earnings recap
Reported
Thu, Feb 26, 2026
EPS actual
$-0.47
EPS est.
$-0.43
EPS surprise
-10.33%
1-day move
-1.53%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Edgewise Therapeutics reported a loss per share that was worse than expected, leading to a slight decline in stock price. Investors may be concerned about the company's current challenges and lack of revenue details. The absence of guidance adds to uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.47 | N/A | -10.33% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed caution regarding the company's near-term performance. They reiterated their commitment to navigating current challenges.
Management highlighted ongoing challenges in the current market environment.
They emphasized a focus on long-term strategy despite short-term setbacks.